Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 10, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their personal holdings of the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The material change reported is an increase in share ownership by specific individuals following the re-investment of dividends paid on April 6, 2006. The transaction price was GBP 14.89 per Ordinary Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of shareholding changes in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Type: Increase in personal share holdings via dividend re-investment.
- Transaction Price: GBP 14.89 per Ordinary Share.
- Dividend Date: April 6, 2006.
- Notified Parties: Mr R Bondy (259 shares), Mr J Heslop (162 shares), Mrs C Pulman (15 shares), Dr D Pulman (80 shares), Mr A Witty (1 share), and Mrs C Witty (305 shares).
- Notification Date: The company and named persons were advised on April 7, 2006.